215 related articles for article (PubMed ID: 34417750)
1. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Mangala LS; Rodriguez-Aguayo C; Bayraktar E; Jennings NB; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2021; 2372():157-168. PubMed ID: 34417750
[TBL] [Abstract][Full Text] [Related]
2. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
3. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
5. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
Martirosyan A; Olesen MJ; Howard KA
Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
[TBL] [Abstract][Full Text] [Related]
6. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
7. Concepts in in vivo siRNA delivery for cancer therapy.
Gondi CS; Rao JS
J Cell Physiol; 2009 Aug; 220(2):285-91. PubMed ID: 19391103
[TBL] [Abstract][Full Text] [Related]
8. Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In Vivo.
Chernikov IV; Meschaninova MI; Chernolovskaya EL
Methods Mol Biol; 2020; 2115():57-77. PubMed ID: 32006394
[TBL] [Abstract][Full Text] [Related]
9. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells.
Hung CF; Lu KC; Cheng TL; Wu RH; Huang LY; Teng CF; Chang WT
Biochem Biophys Res Commun; 2006 Aug; 346(3):707-20. PubMed ID: 16793020
[TBL] [Abstract][Full Text] [Related]
10. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic siRNA: principles, challenges, and strategies.
Gavrilov K; Saltzman WM
Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
[TBL] [Abstract][Full Text] [Related]
12. Significance and applications of nanoparticles in siRNA delivery for cancer therapy.
Ali HM; Urbinati G; Raouane M; Massaad-Massade L
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):403-12. PubMed ID: 22943120
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA-based molecular therapy of cancers.
Guo W; Chen W; Yu W; Huang W; Deng W
Chin J Cancer; 2013 Sep; 32(9):488-93. PubMed ID: 23327796
[TBL] [Abstract][Full Text] [Related]
14. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
15. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
16. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Aigner A
Appl Microbiol Biotechnol; 2007 Aug; 76(1):9-21. PubMed ID: 17457539
[TBL] [Abstract][Full Text] [Related]
17. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
18. Relative Quantification of siRNA Strand Loading into Ago2 for Design of Highly Active siRNAs.
Angart PA; Adu-Berchie K; Carlson RJ; Vocelle DB; Chan C; Walton SP
Methods Mol Biol; 2019; 1974():41-56. PubMed ID: 31098994
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
[TBL] [Abstract][Full Text] [Related]
20. siRNA delivery for the treatment of ovarian cancer.
Goldberg MS
Methods; 2013 Sep; 63(2):95-100. PubMed ID: 23403216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
